UA77166C2 - Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants) - Google Patents

Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants) Download PDF

Info

Publication number: UA77166C2
Authority: UA; Ukraine
Prior art keywords: hydrogen; group; still; sho; fluorine
Prior art date: 2001-01-09

Application number

UA2003076135A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Pliva Istrazivacki Inst D O O

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-09

Filing date

2002-03-01

Publication date

2006-11-15

2002-03-01 Application filed by Pliva Istrazivacki Inst D O O filed Critical Pliva Istrazivacki Inst D O O

2006-11-15 Publication of UA77166C2 publication Critical patent/UA77166C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 118
230000003110 anti-inflammatory effect Effects 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 14
238000002360 preparation method Methods 0.000 title description 9
238000011861 anti-inflammatory therapy Methods 0.000 title 1
210000002865 immune cell Anatomy 0.000 title 1
241001465754 Metazoa Species 0.000 claims abstract description 9
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims description 246
229910052739 hydrogen Inorganic materials 0.000 claims description 246
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 125
150000002431 hydrogen Chemical class 0.000 claims description 82
229910052731 fluorine Inorganic materials 0.000 claims description 70
239000011737 fluorine Substances 0.000 claims description 69
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 66
125000004432 carbon atom Chemical group C* 0.000 claims description 57
229910052736 halogen Inorganic materials 0.000 claims description 57
150000002367 halogens Chemical class 0.000 claims description 57
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 52
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 51
229910052760 oxygen Inorganic materials 0.000 claims description 47
239000001301 oxygen Substances 0.000 claims description 47
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 46
125000000217 alkyl group Chemical group 0.000 claims description 41
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
229910052700 potassium Inorganic materials 0.000 claims description 37
239000003120 macrolide antibiotic agent Substances 0.000 claims description 35
150000003431 steroids Chemical class 0.000 claims description 33
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 26
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 25
238000006243 chemical reaction Methods 0.000 claims description 25
239000000460 chlorine Substances 0.000 claims description 25
229910052801 chlorine Inorganic materials 0.000 claims description 25
125000000753 cycloalkyl group Chemical group 0.000 claims description 24
125000003277 amino group Chemical group 0.000 claims description 22
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 19
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 19
229910052794 bromium Inorganic materials 0.000 claims description 19
150000003254 radicals Chemical class 0.000 claims description 18
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 15
229910052740 iodine Inorganic materials 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
230000004054 inflammatory process Effects 0.000 claims description 11
206010061218 Inflammation Diseases 0.000 claims description 10
125000003118 aryl group Chemical group 0.000 claims description 10
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
230000002757 inflammatory effect Effects 0.000 claims description 8
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 7
230000009471 action Effects 0.000 claims description 7
125000003342 alkenyl group Chemical group 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
229940125773 compound 10 Drugs 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
208000011231 Crohn disease Diseases 0.000 claims description 6
208000010668 atopic eczema Diseases 0.000 claims description 6
150000001735 carboxylic acids Chemical class 0.000 claims description 6
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 6
230000004968 inflammatory condition Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
238000003786 synthesis reaction Methods 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 4
230000032050 esterification Effects 0.000 claims description 4
238000005886 esterification reaction Methods 0.000 claims description 4
210000004969 inflammatory cell Anatomy 0.000 claims description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 3
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
206010010741 Conjunctivitis Diseases 0.000 claims description 3
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
201000004624 Dermatitis Diseases 0.000 claims description 3
206010012434 Dermatitis allergic Diseases 0.000 claims description 3
208000000592 Nasal Polyps Diseases 0.000 claims description 3
201000009053 Neurodermatitis Diseases 0.000 claims description 3
208000003251 Pruritus Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010039085 Rhinitis allergic Diseases 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
125000002252 acyl group Chemical group 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
201000010105 allergic rhinitis Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
206010009887 colitis Diseases 0.000 claims description 3
229940126543 compound 14 Drugs 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000011593 sulfur Chemical group 0.000 claims description 3
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims description 2
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 2
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 claims description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 2
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 2
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 2
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 2
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 2
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 2
229940126657 Compound 17 Drugs 0.000 claims description 2
241000159610 Roya <green alga> Species 0.000 claims description 2
230000004913 activation Effects 0.000 claims description 2
239000013543 active substance Substances 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 2
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
239000012964 benzotriazole Substances 0.000 claims description 2
229940125904 compound 1 Drugs 0.000 claims description 2
229940125797 compound 12 Drugs 0.000 claims description 2
229940125758 compound 15 Drugs 0.000 claims description 2
229940126142 compound 16 Drugs 0.000 claims description 2
229940125782 compound 2 Drugs 0.000 claims description 2
229940125810 compound 20 Drugs 0.000 claims description 2
229940126086 compound 21 Drugs 0.000 claims description 2
229940126208 compound 22 Drugs 0.000 claims description 2
229940125833 compound 23 Drugs 0.000 claims description 2
229940125961 compound 24 Drugs 0.000 claims description 2
229940125846 compound 25 Drugs 0.000 claims description 2
229940125851 compound 27 Drugs 0.000 claims description 2
229940125898 compound 5 Drugs 0.000 claims description 2
ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
125000005647 linker group Chemical group 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims 18
125000001183 hydrocarbyl group Chemical group 0.000 claims 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 9
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
239000011261 inert gas Substances 0.000 claims 6
101100209990 Rattus norvegicus Slc18a2 gene Proteins 0.000 claims 3
101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 claims 2
102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 claims 2
239000011049 pearl Substances 0.000 claims 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
101500020117 Aedes aegypti Sialokinin Proteins 0.000 claims 1
241001516584 Andrya Species 0.000 claims 1
241000239290 Araneae Species 0.000 claims 1
241001211977 Bida Species 0.000 claims 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 claims 1
101000808896 Caenorhabditis elegans Potential E3 ubiquitin-protein ligase ariadne-2 Proteins 0.000 claims 1
240000007681 Catha edulis Species 0.000 claims 1
235000006696 Catha edulis Nutrition 0.000 claims 1
241000132536 Cirsium Species 0.000 claims 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 1
101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 claims 1
244000025221 Humulus lupulus Species 0.000 claims 1
235000008694 Humulus lupulus Nutrition 0.000 claims 1
WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 claims 1
241001214257 Mene Species 0.000 claims 1
241001657788 Orya Species 0.000 claims 1
241001387976 Pera Species 0.000 claims 1
244000097202 Rathbunia alamosensis Species 0.000 claims 1
235000009776 Rathbunia alamosensis Nutrition 0.000 claims 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 claims 1
240000005481 Salvia hispanica Species 0.000 claims 1
235000001498 Salvia hispanica Nutrition 0.000 claims 1
241000979389 Scherya Species 0.000 claims 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
244000191761 Sida cordifolia Species 0.000 claims 1
241000350393 Sinna Species 0.000 claims 1
241001415849 Strigiformes Species 0.000 claims 1
241001424341 Tara spinosa Species 0.000 claims 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 1
101100020289 Xenopus laevis koza gene Proteins 0.000 claims 1
241001377938 Yara Species 0.000 claims 1
240000000038 Ziziphus mauritiana Species 0.000 claims 1
235000006545 Ziziphus mauritiana Nutrition 0.000 claims 1
239000012190 activator Substances 0.000 claims 1
235000015241 bacon Nutrition 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 claims 1
ZJRWDIJRKKXMNW-UHFFFAOYSA-N carbonic acid;cobalt Chemical compound [Co].OC(O)=O ZJRWDIJRKKXMNW-UHFFFAOYSA-N 0.000 claims 1
JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 claims 1
235000014167 chia Nutrition 0.000 claims 1
229910000001 cobalt(II) carbonate Inorganic materials 0.000 claims 1
235000021186 dishes Nutrition 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
208000028774 intestinal disease Diseases 0.000 claims 1
230000007803 itching Effects 0.000 claims 1
239000004033 plastic Substances 0.000 claims 1
229920003023 plastic Polymers 0.000 claims 1
235000008001 rakum palm Nutrition 0.000 claims 1
239000011435 rock Substances 0.000 claims 1
229910052711 selenium Inorganic materials 0.000 claims 1
239000004071 soot Substances 0.000 claims 1
239000004575 stone Substances 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 abstract description 4
239000000543 intermediate Substances 0.000 description 27
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
239000013078 crystal Substances 0.000 description 22
210000004027 cell Anatomy 0.000 description 17
239000000243 solution Substances 0.000 description 16
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
239000002609 medium Substances 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 11
230000000694 effects Effects 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
239000000047 product Substances 0.000 description 8
150000002430 hydrocarbons Chemical group 0.000 description 7
229910000027 potassium carbonate Inorganic materials 0.000 description 7
230000003637 steroidlike Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
210000001541 thymus gland Anatomy 0.000 description 6
230000002411 adverse Effects 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
239000012264 purified product Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229940117173 croton oil Drugs 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229940041033 macrolides Drugs 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
206010014025 Ear swelling Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
208000030880 Nose disease Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
239000006071 cream Substances 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
210000001156 gastric mucosa Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
-1 hydrocarbon radical Chemical class 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000714230 Avian leukemia virus Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000002568 Capsicum frutescens Nutrition 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000301682 Heliotropium curassavicum Species 0.000 description 1
235000015854 Heliotropium curassavicum Nutrition 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
244000131360 Morinda citrifolia Species 0.000 description 1
101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
240000008790 Musa x paradisiaca Species 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000956335 Rysops Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
241001453327 Xanthomonadaceae Species 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000002804 anti-anaphylactic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
235000021015 bananas Nutrition 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000011449 brick Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000004657 carbamic acid derivatives Chemical group 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002170 ethers Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012909 foetal bovine serum Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
230000008187 negative regulation of interleukin-2 production Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000017524 noni Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000002893 slag Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
150000003429 steroid acids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
JVFFWGJAAQAIBS-UHFFFAOYSA-K trisodium 2,2-dioctyl-3-sulfonatobutanedioate Chemical compound [Na+].C(CCCCCCC)C(C(C(=O)[O-])S(=O)(=O)[O-])(C(=O)[O-])CCCCCCCC.[Na+].[Na+] JVFFWGJAAQAIBS-UHFFFAOYSA-K 0.000 description 1
150000003672 ureas Chemical group 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2003076135A 2001-01-09 2002-03-01 Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants) UA77166C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HR20010018A HRP20010018A2 (en)	2001-01-09	2001-01-09	Novel anti-inflammatory compounds
PCT/HR2002/000001 WO2002055531A1 (en)	2001-01-09	2002-01-03	Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Publications (1)

Publication Number	Publication Date
UA77166C2 true UA77166C2 (en)	2006-11-15

Family

ID=10947235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003076135A UA77166C2 (en)	2001-01-09	2002-03-01	Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants)

Country Status (23)

Country	Link
US (2)	US7446097B2 (pl)
EP (1)	EP1351973B1 (pl)
JP (1)	JP4474101B2 (pl)
CN (1)	CN1269836C (pl)
AR (1)	AR035727A1 (pl)
AT (1)	ATE462713T1 (pl)
BG (1)	BG108073A (pl)
BR (1)	BR0206347A (pl)
CA (1)	CA2434009C (pl)
CZ (1)	CZ20031825A3 (pl)
DE (1)	DE60235794D1 (pl)
EA (1)	EA007061B1 (pl)
EE (1)	EE05333B1 (pl)
ES (1)	ES2342364T3 (pl)
GE (1)	GEP20053607B (pl)
HR (1)	HRP20010018A2 (pl)
HU (1)	HUP0500180A3 (pl)
IL (1)	IL156673A0 (pl)
PL (1)	PL207636B1 (pl)
RS (1)	RS51308B (pl)
SK (1)	SK9792003A3 (pl)
UA (1)	UA77166C2 (pl)
WO (1)	WO2002055531A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002109169A (ja) *	2000-09-29	2002-04-12	Hitachi Ltd	作業支援方法並びにシステム及び作業支援方法を記録した記録媒体
AU2003219770B2 (en)	2002-02-15	2008-10-09	Merckle Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7271154B2 (en)	2002-02-15	2007-09-18	Merckle Gmbh	Antibiotic conjugates
EP1483579A4 (en)	2002-02-15	2006-07-12	Merckle Gmbh	CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
EP1521763A2 (en) *	2002-07-08	2005-04-13	Pliva - Istrazivacki Institut d.o.o.	Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
AU2003264917A1 (en)	2002-07-08	2004-01-23	Pliva - Istrazivacki Institut D.O.O.	Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
RS20050008A (sr) *	2002-07-08	2007-06-04	Pliva-Istraživački Institut D.O.O.,	Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
HRP20030324A2 (en)	2003-04-24	2005-02-28	Pliva-Istra�iva�ki institut d.o.o.	Compounds of antiinflammatory effect
WO2005030227A1 (en)	2003-09-23	2005-04-07	Enanta Pharmaceuticals, Inc.	9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES
JP4737495B2 (ja) *	2004-01-14	2011-08-03	塩野義製薬株式会社	エリスロマイシン誘導体
KR20070046917A (ko) *	2004-08-12	2007-05-03	글락소스미쓰클라인 이스트라지바치키 센타 자그레브 디.오.오.	위장관의 염증성 질환의 치료를 위한 세포-특이적컨쥬게이트의 용도
US20060183696A1 (en) *	2004-08-12	2006-08-17	Pliva-Istrazivacki Institut D.O.O.	Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
US7402568B2 (en)	2004-09-29	2008-07-22	Enanta Pharmaceuticals, Inc.	Bicyclic 9a-azalide derivatives
ES2337915T3 (es) *	2004-10-27	2010-04-30	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	Conjugados con adtividad antiinflamatoria.
US7271155B2 (en)	2005-01-07	2007-09-18	Enanta Pharmaceuticals, Inc.	9A, 11-2C-bicyclic 9a-azalide derivatives
US20080249034A1 (en) *	2005-03-21	2008-10-09	Zambon S.P.A.	Use of Macrolides for Treating Intestinal Inflammation
WO2011116312A1 (en) *	2010-03-19	2011-09-22	Catabasis Pharmaceuticals, Inc.	Fatty acid macrolide derivatives and their uses
EP2948152A4 (en) *	2013-01-23	2016-12-14	Sphaera Pharma Private Ltd	NOVEL COMPOUNDS OF 11-BETA HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES RELATED TO MITOCHONDRIA DYSFUNCTION OR ADDITIONAL
WO2016013030A2 (en)	2014-07-23	2016-01-28	Sphaera Pharma Pvt. Ltd.	Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
GB201520419D0 (en)	2015-11-19	2016-01-06	Epi Endo Pharmaceuticals Ehf	Compounds
WO2023248010A2 (en) *	2022-06-23	2023-12-28	Synovo Gmbh	Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4710495A (en)	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
HU198913B (en)	1987-09-03	1989-12-28	Pliva Pharm & Chem Works	Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
JPH01163124A (ja) *	1987-12-21	1989-06-27	Yamayuu Seikatsushiya:Kk	外用鎮痛消炎消腫消膿剤
SE9100342D0 (sv)	1991-02-04	1991-02-04	Astra Ab	Novel steroid esters
SE9100341D0 (sv)	1991-02-04	1991-02-04	Astra Ab	Novel steroids
GB9225923D0 (en)	1992-12-11	1993-02-03	Rhone Poulenc Rorer Ltd	New compositions of matter
DE69311742T2 (de)	1992-12-24	1998-01-08	Rhone Poulenc Rorer Ltd	Neue steroide
AU3192695A (en)	1994-08-12	1996-03-07	Taisho Pharmaceutical Co., Ltd.	Interleukin-5 production inhibitor
WO1996004919A1 (en)	1994-08-12	1996-02-22	Taisho Pharmaceutical Co., Ltd.	Interleukin-5 production inhibitor
DE19542949A1 (de)	1995-11-17	1997-07-17	Hilti Ag	Bolzen zum Eintreiben in harte Aufnahmewerkstoffe
CA2252886C (en)	1996-04-26	2008-02-12	Massachusetts Institute Of Technology	Three-hybrid screening assay
FR2776927B1 (fr) *	1998-04-07	2002-07-05	Univ Paris Curie	Compositions pour la vectorisation de molecules
US6288234B1 (en) *	1998-06-08	2001-09-11	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
WO1999064040A1 (en) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel polyene macrolide compounds and uses
IT1306205B1 (it)	1999-01-15	2001-05-30	Zambon Spa	Macrolidi ad attivita' antiinfiammatoria.
AU2003219770B2 (en)	2002-02-15	2008-10-09	Merckle Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

2001
- 2001-01-09 HR HR20010018A patent/HRP20010018A2/hr not_active Application Discontinuation
2002
- 2002-01-03 EP EP02729470A patent/EP1351973B1/en not_active Expired - Lifetime
- 2002-01-03 HU HU0500180A patent/HUP0500180A3/hu unknown
- 2002-01-03 PL PL363478A patent/PL207636B1/pl unknown
- 2002-01-03 DE DE60235794T patent/DE60235794D1/de not_active Expired - Lifetime
- 2002-01-03 JP JP2002556599A patent/JP4474101B2/ja not_active Expired - Fee Related
- 2002-01-03 EE EEP200300293A patent/EE05333B1/xx not_active IP Right Cessation
- 2002-01-03 AT AT02729470T patent/ATE462713T1/de not_active IP Right Cessation
- 2002-01-03 US US10/250,934 patent/US7446097B2/en not_active Expired - Fee Related
- 2002-01-03 IL IL15667302A patent/IL156673A0/xx unknown
- 2002-01-03 SK SK979-2003A patent/SK9792003A3/sk unknown
- 2002-01-03 EA EA200300781A patent/EA007061B1/ru not_active IP Right Cessation
- 2002-01-03 CN CNB02804715XA patent/CN1269836C/zh not_active Expired - Fee Related
- 2002-01-03 BR BR0206347-6A patent/BR0206347A/pt not_active Application Discontinuation
- 2002-01-03 CZ CZ20031825A patent/CZ20031825A3/cs unknown
- 2002-01-03 ES ES02729470T patent/ES2342364T3/es not_active Expired - Lifetime
- 2002-01-03 CA CA002434009A patent/CA2434009C/en not_active Expired - Fee Related
- 2002-01-03 GE GE5260A patent/GEP20053607B/en unknown
- 2002-01-03 RS YUP-552/03A patent/RS51308B/sr unknown
- 2002-01-03 WO PCT/HR2002/000001 patent/WO2002055531A1/en not_active Ceased
- 2002-01-08 AR ARP020100040A patent/AR035727A1/es active IP Right Grant
- 2002-03-01 UA UA2003076135A patent/UA77166C2/uk unknown
2003
- 2003-08-07 BG BG108073A patent/BG108073A/bg unknown
2008
- 2008-09-16 US US12/211,213 patent/US7928078B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20040198677A1 (en)	2004-10-07
CA2434009A1 (en)	2002-07-18
IL156673A0 (en)	2004-01-04
HK1065320A1 (en)	2005-02-18
ATE462713T1 (de)	2010-04-15
EE05333B1 (et)	2010-08-16
SK9792003A3 (en)	2004-01-08
WO2002055531A1 (en)	2002-07-18
EE200300293A (et)	2003-10-15
HRP20010018A2 (en)	2002-12-31
EP1351973B1 (en)	2010-03-31
CZ20031825A3 (cs)	2003-11-12
CN1491230A (zh)	2004-04-21
YU55203A (sh)	2006-03-03
AR035727A1 (es)	2004-07-07
HUP0500180A2 (en)	2006-09-28
ES2342364T3 (es)	2010-07-06
PL207636B1 (pl)	2011-01-31
HUP0500180A3 (en)	2009-12-28
CA2434009C (en)	2009-09-29
DE60235794D1 (de)	2010-05-12
JP4474101B2 (ja)	2010-06-02
US7446097B2 (en)	2008-11-04
GEP20053607B (en)	2005-09-12
EA007061B1 (ru)	2006-06-30
US7928078B2 (en)	2011-04-19
EA200300781A1 (ru)	2003-12-25
EP1351973A1 (en)	2003-10-15
PL363478A1 (pl)	2004-11-15
BR0206347A (pt)	2004-02-10
CN1269836C (zh)	2006-08-16
BG108073A (bg)	2005-05-31
RS51308B (sr)	2010-12-31
US20090105163A1 (en)	2009-04-23
JP2004518670A (ja)	2004-06-24

Publication	Publication Date	Title
UA77166C2 (en)	2006-11-15	Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants)
CN112533893B (zh)	2023-12-22	阳离子性脂质
US7157433B2 (en)	2007-01-02	Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules
TWI505830B (zh)	2015-11-01	１７－羥基－１７－五氟乙基－雌甾－４，９（１０）－二烯－１１－芳基衍生物、其製造方法及其治療疾病之用途
US9428540B2 (en)	2016-08-30	Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents
US20190135853A1 (en)	2019-05-09	6-Substituted Estradiol Derivatives and Methods of Use
US8629130B2 (en)	2014-01-14	6-substituted estradiol derivatives and methods of use
CN101402667B (zh)	2012-05-30	糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
US20140199378A1 (en)	2014-07-17	New natural and synthetic compounds for treating cancer and other diseases
US20080119447A1 (en)	2008-05-22	6-alkoxyalkyl estradiol derivatives and methods of use
CA2670773C (en)	2013-01-22	6-alkoxyalkyl estradiol derivatives and methods of use
CN114702544B (zh)	2024-01-30	一种氨基甾体化合物及其制备方法和应用
US20260092081A1 (en)	2026-04-02	Compounds for use in the treatment of liver disease
CN111574580A (zh)	2020-08-25	一种人参皂苷衍生物及其合成方法与应用
EP2188301A2 (en)	2010-05-26	Novel steroidal esters of 17-oximino-5-androsten-3 beta-ol
HK1139315A (en)	2010-09-17	6-alkoxyalkyl estradiol derivatives and its use